Psychopharmacology
November 1, 2025
Marta De Felice, Hanna J Szkudlarek, Matthew J Jones et al.
RATIONALE: Chronic cannabis during adolescence is associated with long-lasting pathological outcomes, and these effects can be remarkably different between the sexes. Preclinical studies in rodents demonstrated that sustained exposure to Δ9-tetrahydrocannabinol (THC), induces sex-specific pathophysiological outcomes. Thus, while males exhibit higher vulnerability to schizophrenia-like...
Translational Psychiatry
October 6, 2025
Hanna J Szkudlarek, Rajkamalpreet Singh Mann, Krystyna Wieczerzak et al.
1 citation
Clinical and pre-clinical evidence demonstrates that adolescent Δ-9-tetrahydrocannabinol (THC) exposure, the primary psychoactive component of cannabis, increases the risk of developing neuropsychiatric symptoms in later life. The medial prefrontal cortex (mPFC) serves as a pathophysiological nexus point underlying many cannabis-related pathophysiological outcomes. Nevertheless, the molecular...
Neuropsychopharmacology
February 2023
Marta De Felice, Chaochao Chen, Mar Rodríguez-ruiz et al.
Chronic exposure to Δ-9-tetrahydrocannabinol (THC) during adolescence is associated with long-lasting cognitive impairments and enhanced susceptibility to anxiety and mood disorders. Previous evidence has revealed functional and anatomical dissociations between the posterior vs. anterior portions of the hippocampal formation, which are classified as the dorsal and ventral regions in rodents,...
eNeuro
2022
Mohammed H Sarikahya, Samantha Cousineau, Marta De Felice et al.
Despite increased prevalence of maternal cannabis use, little is understood regarding potential long-term effects of prenatal cannabis exposure (PCE) on neurodevelopmental outcomes. While neurodevelopmental cannabis exposure increases the risk of developing affective/mood disorders in adulthood, the precise neuropathophysiological mechanisms in male and female offspring are largely unknown....
Progress in Neuro-Psychopharmacology and Biological Psychiatry
January 10, 2021
Hanna J Szkudlarek, Mar Rodríguez-ruiz, Roger Hudson et al.
Clinical and pre-clinical evidence demonstrates divergent psychotropic effects of THC vs. CBD. While THC can induce perceptual distortions and anxiogenic effects, CBD displays antipsychotic and anxiolytic properties. A key brain region responsible for regulation of cognition and affect, the medial prefrontal cortex (PFC), is strongly modulated by cannabinoids, suggesting that these dissociable...
Psychopharmacology
February 2018
Roger Hudson, Walter J Rushlow, Steven R Laviolette
Growing clinical and preclinical evidence suggests a potential role for the phytocannabinoid cannabidiol (CBD) as a pharmacotherapy for various neuropsychiatric disorders. In contrast, delta-9-tetrahydrocannabinol (THC), the primary psychoactive component in cannabis, is associated with acute and neurodevelopmental propsychotic side effects through its interaction with central cannabinoid type...
Neuroscience & Biobehavioral Reviews
April 2017
Justine Renard, Christopher Norris, Walter J Rushlow et al.
Growing clinical and pre-clinical evidence points to a critical role for cannabidiol (CBD), the largest phytochemical component of cannabis, as a potential pharmacotherapy for various neuropsychiatric disorders. In contrast to delta-9-tetrahydrocannabinol (THC), which is associated with acute and neurodevelopmental pro-psychotic side-effects, CBD possesses no known psychoactive or...
Cerebral Cortex
February 1, 2017
Justine Renard, Laura G Rosen, Michael Loureiro et al.
Considerable evidence suggests that adolescent exposure to delta-9-tetrahydrocanabinol (THC), the psychoactive component in marijuana, increases the risk of developing schizophrenia-related symptoms in early adulthood. In the present study, we used a combination of behavioral and molecular analyses with in vivo neuronal electrophysiology to compare the long-term effects of adolescent versus...